Phase II Targeted Agent and Profiling Utilization Registry Study (TAPUR)
Summary
Due to the high volume of sites for this trial, please note that some of the sites may no longer be accruing. We update this information as we become aware of site closures; please contact the site for verification.
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
Biomarker testing to determine which treatment each patient will receive must be completed prior to screening for the trial.
General Information
NCT#: NCT02693535
Study ID: Pro00014171
Trial Phase: Phase II
Trial Sponsor: Pfizer, Genentech, Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Bayer, Merck Sharp & Dohme Corp., Boehringer Ingelheim Pharmaceuticals, Inc., American Society of Clinical Oncology (ASCO), Seagen Inc.
Therapies Used in This Trial: Ipilimumab, Temsirolimus, Olaparib, Trastuzumab, Cobimetinib, Nivolumab, Regorafenib, Pembrolizumab, Afatinib, Entrectinib, Crizotinib, Palbociclib, Vemurafenib, Atezolizumab, Abemaciclib, Larotrectinib, Talazoparib
Sign In